lofepramine has been researched along with Multiple Sclerosis in 4 studies
Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether combination therapy with lofepramine, L-phenylalanine, and intramuscular vitamin B-12 (the "Cari Loder regime") reduces disability in patients with multiple sclerosis." | 9.10 | A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. ( Chaudhuri, KR; Davidson, DL; Wade, DT; Young, CA, 2002) |
| "In a randomized, placebo-controlled double-blind trial a combination of lofepramine, phenylalanine and vitamin B(12) was found to be effective in relieving the symptoms of multiple sclerosis (MS)." | 9.10 | Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems. ( Allawi, J; Horrobin, DF; Loder, C, 2002) |
| "As part of a large, randomized placebo-controlled trial of inpatients with multiple sclerosis (MS), a subsample of 15 underwent cerebral MRI at baseline and 6-months (eight on lofepramine and l-phenylalanine; seven on placebo)." | 9.09 | MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. ( Al Saffar, BY; Bydder, GM; Chaudhuri, KR; Curati, WL; Hajnal, JV; Horrobin, DF; Mitchell, L; Puri, BK; White, SJ, 2001) |
| "To determine whether combination therapy with lofepramine, L-phenylalanine, and intramuscular vitamin B-12 (the "Cari Loder regime") reduces disability in patients with multiple sclerosis." | 5.10 | A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. ( Chaudhuri, KR; Davidson, DL; Wade, DT; Young, CA, 2002) |
| "In a randomized, placebo-controlled double-blind trial a combination of lofepramine, phenylalanine and vitamin B(12) was found to be effective in relieving the symptoms of multiple sclerosis (MS)." | 5.10 | Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems. ( Allawi, J; Horrobin, DF; Loder, C, 2002) |
| "As part of a large, randomized placebo-controlled trial of inpatients with multiple sclerosis (MS), a subsample of 15 underwent cerebral MRI at baseline and 6-months (eight on lofepramine and l-phenylalanine; seven on placebo)." | 5.09 | MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. ( Al Saffar, BY; Bydder, GM; Chaudhuri, KR; Curati, WL; Hajnal, JV; Horrobin, DF; Mitchell, L; Puri, BK; White, SJ, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wade, DT | 1 |
| Young, CA | 1 |
| Chaudhuri, KR | 2 |
| Davidson, DL | 1 |
| Loder, C | 1 |
| Allawi, J | 1 |
| Horrobin, DF | 2 |
| Krupp, L | 1 |
| Puri, BK | 1 |
| Bydder, GM | 1 |
| Al Saffar, BY | 1 |
| Curati, WL | 1 |
| White, SJ | 1 |
| Mitchell, L | 1 |
| Hajnal, JV | 1 |
3 trials available for lofepramine and Multiple Sclerosis
| Article | Year |
|---|---|
A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Disability Evaluation; Double-Blind Metho | 2002 |
Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems.
Topics: Adrenergic Fibers; Adrenergic Uptake Inhibitors; Antidepressive Agents; Chronic Disease; Double-Blin | 2002 |
MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine.
Topics: Adult; Antidepressive Agents, Tricyclic; Atrophy; Cerebral Cortex; Drug Therapy, Combination; Female | 2001 |
1 other study available for lofepramine and Multiple Sclerosis
| Article | Year |
|---|---|
Managing MS. While a cure is sought, people with MS can help themselves.
Topics: Antidepressive Agents, Tricyclic; Drug Therapy, Combination; Exercise Therapy; Humans; Lofepramine; | 2002 |